OptimizeRx Corporation(OPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OPRX OptimizeRx Corporation

Pre-Market Trading 12-23 09:27:46 EST

4.91

+0.16

+3.37%

High5.06	Low4.62	Vol290.13K
Open4.76	D1 Closing4.75	Amplitude9.26%
Mkt Cap90.45M	Tradable Cap79.08M	Total Shares18.42M
T/O1.42M	T/O Rate1.80%	Tradable Shares16.11M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"OPRX","market":"US","secType":"STK","nameCN":"OptimizeRx Corporation","latestPrice":4.91,"timestamp":1734728400000,"preClose":4.75,"halted":0,"volume":290125,"delay":0,"floatShares":16106258,"shares":18420906,"eps":-1.343322,"marketStatus":"Pre-Market Trading","change":0.16,"latestTime":"12-23 09:27:46 EST","open":4.76,"high":5.06,"low":4.62,"amount":1424869.9781,"amplitude":0.092632,"askPrice":7.11,"askSize":400,"bidPrice":4.02,"bidSize":15,"shortable":3,"etf":0,"ttmEps":-1.343322,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1734964200000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":4.91,"postHourTrading":{"tag":"盘后","latestPrice":4.91,"preClose":4.91,"latestTime":"16:07 EST","volume":21779,"amount":106934.89,"timestamp":1734728835828},"volumeRatio":0.8747204359718883,"impliedVol":1.1044,"impliedVolPercentile":0.908},"requestUrl":"/m/hq/s/OPRX/tweets","defaultTab":"tweets","newsList":[{"id":"2493768230","title":"OptimizeRx announces departure of CEO Febbo, appoint Silvestro as interim CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2493768230","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493768230?lang=en_us&edition=fundamental","pubTime":"2024-12-23 21:50","pubTimestamp":1734961813,"startTime":"0","endTime":"0","summary":"OptimizeRx (OPRX) announced that William Febbo, Chief Executive Officer, CEO, and Board Member, will be departing the Company, effective as of Dece...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/optimizerx-announces-departure-of-ceo-febbo-appoint-silvestro-as-interim-ceo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/optimizerx-announces-departure-of-ceo-febbo-appoint-silvestro-as-interim-ceo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4167","OPRX"],"gpt_icon":0},{"id":"2493750277","title":"OptimizeRx Corp: Reaffirms Its Financial Guidance for Full Year 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2493750277","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493750277?lang=en_us&edition=fundamental","pubTime":"2024-12-23 21:45","pubTimestamp":1734961500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nTUA9HCN9P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OPRX","BK4167"],"gpt_icon":0},{"id":"2493750274","title":"OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2493750274","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493750274?lang=en_us&edition=fundamental","pubTime":"2024-12-23 21:45","pubTimestamp":1734961500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nTUA9HCN9P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4167","OPRX"],"gpt_icon":0},{"id":"2493502727","title":"OptimizeRx: Expects FY Results Will Come in at Higher End of Its Guidance Range for Revenue & Adjusted Ebitda","url":"https://stock-news.laohu8.com/highlight/detail?id=2493502727","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493502727?lang=en_us&edition=fundamental","pubTime":"2024-12-23 21:45","pubTimestamp":1734961500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nTUA9HCN9P:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OPRX","BK4167"],"gpt_icon":0},{"id":"2493750203","title":"Press Release: OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2493750203","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493750203?lang=en_us&edition=fundamental","pubTime":"2024-12-23 21:45","pubTimestamp":1734961500,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Dec. 23, 2024  -- OptimizeRx Corp.  , a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals  and patients, today announced that William J. Febbo, Chief Executive Officer  and Board Member, will be departing the Company, effective as of December 31, 2024, to pursue other opportunities. Mr. Febbo will provide the Company with advisory services through March 31, 2025. The Company's Board of Directors has retained a search firm to assist in this transition.\"The time is right to pass the reins on to an incredible team, ready to carry the legacy forward with strength and purpose,\" underscored Mr. Febbo. \"With a clear market opportunity and the ability to deliver, they have my ongoing and unwavering support.\". OptimizeRx provides best-in-class health technology that enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","CEO","OPRX"],"gpt_icon":0},{"id":"2492444847","title":"Stephens Initiates Coverage on OptimizeRx With Equal Weight Rating, $5.50 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2492444847","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492444847?lang=en_us&edition=fundamental","pubTime":"2024-12-20 21:07","pubTimestamp":1734700072,"startTime":"0","endTime":"0","summary":"OptimizeRx (OPRX) has an average rating of Buy and mean price target of $10.36, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPRX"],"gpt_icon":0},{"id":"2492484258","title":"OptimizeRx initiated with an Equal Weight at Stephens","url":"https://stock-news.laohu8.com/highlight/detail?id=2492484258","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492484258?lang=en_us&edition=fundamental","pubTime":"2024-12-20 05:30","pubTimestamp":1734643850,"startTime":"0","endTime":"0","summary":"Stephens initiated coverage of OptimizeRx (OPRX) with an Equal Weight rating and $5.50 price target The firm says the company’s “evolving” direct-t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/optimizerx-initiated-with-an-equal-weight-at-stephens?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/optimizerx-initiated-with-an-equal-weight-at-stephens?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPRX","BK4167"],"gpt_icon":0},{"id":"2492968571","title":"Analysts Conflicted on These Healthcare Names: OptimizeRx (OPRX) and Universal Health (UHS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2492968571","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492968571?lang=en_us&edition=fundamental","pubTime":"2024-12-17 22:10","pubTimestamp":1734444614,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on OptimizeRx (OPRX – Research Report) and Universal Health (UHS – R...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-optimizerx-oprx-and-universal-health-uhs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-optimizerx-oprx-and-universal-health-uhs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4585","UHS","OPRX","HCSG","BK4185","BK4167","BK4588"],"gpt_icon":0},{"id":"2484062741","title":"OptimizeRx to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2484062741","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484062741?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:30","pubTimestamp":1731933000,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Nov. 18, 2024  -- OptimizeRx Corp. ,a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional  and patients, today announced that management will participate in the following upcoming investor conferences:. 13th Annual ROTH Technology Conference, New York City, November 19th – 20th, 2024. Canaccord Genuity’s 2024 CG MedTech, Diagnostics and Digital Health & Services Forum, New York City, November 21st, 2024. To request a meeting or for more details about the conferences please reach out to your institutional contact or email.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/AMImFdBNZ.vouVAh4J9vIQ--~B/aD0zMDA7dz0xMjc1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/213f5d3738e6580d338354a848b3f901","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/AMImFdBNZ.vouVAh4J9vIQ--~B/aD0zMDA7dz0xMjc1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/213f5d3738e6580d338354a848b3f901"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/optimizerx-participate-upcoming-investor-conferences-123000174.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4167","OPRX"],"gpt_icon":0},{"id":"2483383174","title":"OptimizeRx Price Target Cut to $16.00/Share From $20.00 by Roth MKM","url":"https://stock-news.laohu8.com/highlight/detail?id=2483383174","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483383174?lang=en_us&edition=fundamental","pubTime":"2024-11-15 00:00","pubTimestamp":1731600000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OPRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2024 11:00 ET (16:00 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPRX"],"gpt_icon":0},{"id":"2483580126","title":"OptimizeRx Is Maintained at Buy by Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2483580126","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483580126?lang=en_us&edition=fundamental","pubTime":"2024-11-14 22:41","pubTimestamp":1731595260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OPRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2024 09:41 ET (14:41 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPRX","SF"],"gpt_icon":0},{"id":"2483871981","title":"RBC Cuts Price Target on OptimizeRx to $7 From $14, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2483871981","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483871981?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:25","pubTimestamp":1731587115,"startTime":"0","endTime":"0","summary":"OptimizeRx (OPRX) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $5 to $20.(MT Newswires covers equity, commodity and economic rese","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPRX"],"gpt_icon":0},{"id":"2483822321","title":"OptimizeRx price target lowered to $5 from $11 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2483822321","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483822321?lang=en_us&edition=fundamental","pubTime":"2024-11-14 18:36","pubTimestamp":1731580562,"startTime":"0","endTime":"0","summary":"Barclays lowered the firm’s price target on OptimizeRx (OPRX) to $5 from $11 and keeps an Equal Weight rating on the shares. The stock dropped 17% ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/optimizerx-price-target-lowered-to-5-from-11-at-barclays?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/optimizerx-price-target-lowered-to-5-from-11-at-barclays?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4167","OPRX"],"gpt_icon":0},{"id":"2483082995","title":"Barclays Sticks to Their Hold Rating for OptimizeRx (OPRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483082995","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483082995?lang=en_us&edition=fundamental","pubTime":"2024-11-14 17:51","pubTimestamp":1731577887,"startTime":"0","endTime":"0","summary":"In a report released today, Stephanie Davis from Barclays maintained a Hold rating on OptimizeRx (OPRX – Research Report), with a price target of $...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-their-hold-rating-for-optimizerx-oprx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-their-hold-rating-for-optimizerx-oprx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPRX"],"gpt_icon":0},{"id":"2483829603","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: PTC Therapeutics (PTCT), Medtronic (MDT) and OptimizeRx (OPRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483829603","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483829603?lang=en_us&edition=fundamental","pubTime":"2024-11-14 17:51","pubTimestamp":1731577885,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on PTC Therapeutics (PTCT – Research Report), Medtronic (MDT – Resea...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-ptc-therapeutics-ptct-medtronic-mdt-and-optimizerx-oprx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-ptc-therapeutics-ptct-medtronic-mdt-and-optimizerx-oprx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPRX","BK4585","LU0976567544.SGD","LU1721428347.USD","PTC","LU0162691827.USD","LU2023251221.USD","LU2506952410.USD","LU1923623000.USD","LU2028103732.USD","LU1951200564.SGD","LU1291159041.SGD","IE00BQXX3C00.GBP","BK4139","BK4167","IE00B3T34201.USD","LU0158827781.USD","BK4588","LU2506952337.HKD","BK4554","LU2089284900.SGD","LU1989764748.USD","BK4533","HCSG","IE00BQXX3D17.EUR","LU0211326755.USD","LU0211326839.USD","LU2362540622.SGD","LU0320765489.SGD","LU1571399168.USD","BK4137","LU0208291251.USD","LU0496365809.HKD","LU0889565916.HKD","MDT","LU0070302665.USD","BK4566","LU0109394709.USD","LU1989764664.SGD","LU2362541513.USD","LU2111349929.HKD","PTCT","LU2362541273.HKD","BK4023","IE00BFXG1179.USD","LU0072461881.USD","BK4576","LU0320765992.SGD","IE00BQXX3F31.USD","LU0158827948.USD"],"gpt_icon":0},{"id":"2483846036","title":"OptimizeRx Corp (OPRX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Shifts ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2483846036","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483846036?lang=en_us&edition=fundamental","pubTime":"2024-11-14 15:15","pubTimestamp":1731568520,"startTime":"0","endTime":"0","summary":"For the complete transcript of the earnings call, please refer to the full earnings call transcript.OptimizeRx Corp  reported a 30% year-over-year increase in revenue, reaching $21.3 million for the third quarter.The company achieved significant cost savings and operational efficiencies following the integration of acquired businesses.OptimizeRx Corp  has expanded its AI capabilities, enhancing its ability to integrate point-of-care and digital media solutions, which positions it well for future market share capture.Q: Can you provide more details on the four clients expected to generate over $10 million each next year?How do these contracts perform from a margin perspective, and are there upfront costs?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/optimizerx-corp-oprx-q3-2024-071520637.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OPRX"],"gpt_icon":0},{"id":"2483489732","title":"OptimizeRx Corp reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483489732","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483489732?lang=en_us&edition=fundamental","pubTime":"2024-11-14 12:16","pubTimestamp":1731557810,"startTime":"0","endTime":"0","summary":"* OptimizeRx Corp    reported quarterly adjusted earnings of 12 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of 9 cents.  T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPRX"],"gpt_icon":0},{"id":"2483862924","title":"OptimizeRx Corp. (OPRX) Surpasses Q3 Earnings Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483862924","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483862924?lang=en_us&edition=fundamental","pubTime":"2024-11-14 06:35","pubTimestamp":1731537309,"startTime":"0","endTime":"0","summary":"OptimizeRx Corp.  came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 100%. A quarter ago, it was expected that this company would post a loss of $0.07 per share when it actually produced earnings of $0.02, delivering a surprise of 128.57%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.OptimizeRx , which belongs to the Zacks Computer - Software industry, posted revenues of $21.31 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 14.55%. This compares to year-ago revenues of $16.33 million. The company has topped consensus revenue estimates just once over the last four quarters.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the perform","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/kz0ozt3ejWMPXKci2JxOBw--~B/aD03NTQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/d7dcbe11345e3f8e5e71e6827fe3c4c9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/kz0ozt3ejWMPXKci2JxOBw--~B/aD03NTQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/d7dcbe11345e3f8e5e71e6827fe3c4c9"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/optimizerx-corp-oprx-surpasses-q3-223509602.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OPRX"],"gpt_icon":0},{"id":"2483868438","title":"OptimizeRx Q3 2024 Adj. EPS $0.12 Beats $0.06 Estimate, Sales $21.309M Miss $24.997M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483868438","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483868438?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:10","pubTimestamp":1731532205,"startTime":"0","endTime":"0","summary":"OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.06 by 100 percent.  The company reported quarterly sales of $21.309 million which missed the analyst","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41954320/optimizerx-q3-2024-adj-eps-0-12-beats-0-06-estimate-sales-21-309m-miss-24-997m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"OptimizeRx Q3 2024 Adj. EPS $0.12 Beats $0.06 Estimate, Sales $21.309M Miss $24.997M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPRX"],"gpt_icon":0},{"id":"2483868695","title":"OptimizeRx Outlook FY24 Revenue to Be Between $88 Mln and $92 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2483868695","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483868695?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:05","pubTimestamp":1731531903,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA4LFP6D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4167","OPRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.optimizerx.com","stockEarnings":[{"period":"1week","weight":-0.016},{"period":"1month","weight":0.1109},{"period":"3month","weight":-0.3769},{"period":"6month","weight":-0.5355},{"period":"1year","weight":-0.6554},{"period":"ytd","weight":-0.6569}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.05463},{"month":2,"riseRate":0.666667,"avgChangeRate":0.055816},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.115451},{"month":4,"riseRate":0.5,"avgChangeRate":-0.074092},{"month":5,"riseRate":0.5,"avgChangeRate":0.099038},{"month":6,"riseRate":0.833333,"avgChangeRate":0.062928},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.02887},{"month":8,"riseRate":0.571429,"avgChangeRate":0.002178},{"month":9,"riseRate":0.428571,"avgChangeRate":0.056563},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.051657},{"month":11,"riseRate":0.571429,"avgChangeRate":0.059021},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.003752}],"exchange":"NASDAQ","name":"OptimizeRx Corporation","nameEN":"OptimizeRx Corporation"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"OptimizeRx Corporation(OPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest OptimizeRx Corporation(OPRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"OptimizeRx Corporation,OPRX,OptimizeRx Corporation股票,OptimizeRx Corporation股票老虎,OptimizeRx Corporation股票老虎国际,OptimizeRx Corporation行情,OptimizeRx Corporation股票行情,OptimizeRx Corporation股价,OptimizeRx Corporation股市,OptimizeRx Corporation股票价格,OptimizeRx Corporation股票交易,OptimizeRx Corporation股票购买,OptimizeRx Corporation股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"OptimizeRx Corporation(OPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest OptimizeRx Corporation(OPRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}